TY - JOUR AU - Bray, F. AU - Ferlay, J. AU - Soerjomataram, I. AU - Siegel, R. L. AU - Torre, L. A. AU - Jemal, A. PY - 2018 DA - 2018// TI - Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21492 DO - 10.3322/caac.21492 ID - Bray2018 ER - TY - JOUR AU - Generali, D. AU - Ardine, M. AU - Strina, C. AU - Milani, M. AU - Cappelletti, M. R. AU - Zanotti, L. PY - 2015 DA - 2015// TI - Neoadjuvant treatment approach: the Rosetta stone for breast Cancer? JO - J Natl Cancer Inst Monogr VL - 2015 UR - https://doi.org/10.1093/jncimonographs/lgv019 DO - 10.1093/jncimonographs/lgv019 ID - Generali2015 ER - TY - JOUR AU - Schneeweiss, A. AU - Chia, S. AU - Hickish, T. AU - Harvey, V. AU - Eniu, A. AU - Hegg, R. PY - 2013 DA - 2013// TI - Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt182 DO - 10.1093/annonc/mdt182 ID - Schneeweiss2013 ER - TY - JOUR AU - Gianni, L. AU - Pienkowski, T. AU - Im, Y. H. AU - Roman, L. AU - Tseng, L. M. AU - Liu, M. C. PY - 2012 DA - 2012// TI - Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(11)70336-9 DO - 10.1016/S1470-2045(11)70336-9 ID - Gianni2012 ER - TY - JOUR AU - De, A. E. AU - Holmes, A. P. AU - Piccartgebhart, M. AU - Holmes, E. AU - Di, C. S. AU - Swaby, R. F. PY - 2014 DA - 2014// TI - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70320-1 DO - 10.1016/S1470-2045(14)70320-1 ID - De2014 ER - TY - JOUR AU - Guarneri, V. AU - Frassoldati, A. AU - Bottini, A. AU - Cagossi, K. AU - Bisagni, G. AU - Sarti, S. PY - 2012 DA - 2012// TI - Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.39.0823 DO - 10.1200/JCO.2011.39.0823 ID - Guarneri2012 ER - TY - JOUR AU - Gianni, L. AU - Pienkowski, T. AU - Im, Y. H. AU - Tseng, L. M. AU - Liu, M. C. AU - Lluch, A. PY - 2016 DA - 2016// TI - 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(16)00163-7 DO - 10.1016/S1470-2045(16)00163-7 ID - Gianni2016 ER - TY - JOUR AU - Azambuja, E. AU - Holmes, A. P. AU - Piccart-Gebhart, M. AU - Holmes, E. AU - Cosimo, S. AU - Swaby, R. F. PY - 2014 DA - 2014// TI - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70320-1 DO - 10.1016/S1470-2045(14)70320-1 ID - Azambuja2014 ER - TY - JOUR AU - Ough, M. AU - Velasco, J. AU - Hieken, T. J. PY - 2011 DA - 2011// TI - A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression JO - Am J Surg VL - 201 UR - https://doi.org/10.1016/j.amjsurg.2010.02.015 DO - 10.1016/j.amjsurg.2010.02.015 ID - Ough2011 ER - TY - JOUR AU - Tamaki, K. AU - Sasano, H. AU - Ishida, T. AU - Miyashita, M. AU - Takeda, M. AU - Amari, M. PY - 2010 DA - 2010// TI - Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients JO - Cancer Sci VL - 101 UR - https://doi.org/10.1111/j.1349-7006.2010.01630.x DO - 10.1111/j.1349-7006.2010.01630.x ID - Tamaki2010 ER - TY - JOUR AU - D'Alfonso, T. AU - Liu, Y. F. AU - Monni, S. AU - Rosen, P. P. AU - Shin, S. J. PY - 2010 DA - 2010// TI - Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed JO - Am J Surg Pathol VL - 34 UR - https://doi.org/10.1097/PAS.0b013e3181d65639 DO - 10.1097/PAS.0b013e3181d65639 ID - D'Alfonso2010 ER - TY - JOUR AU - Park, S. Y. AU - Kim, K. S. AU - Lee, T. G. AU - Park, S. S. AU - Kim, S. M. AU - Han, W. PY - 2009 DA - 2009// TI - The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer JO - Am J Surg VL - 197 UR - https://doi.org/10.1016/j.amjsurg.2007.11.024 DO - 10.1016/j.amjsurg.2007.11.024 ID - Park2009 ER - TY - JOUR AU - Li, J. AU - Zhang, B. -. N. AU - Fan, J. -. H. AU - Pang, Y. AU - Zhang, P. AU - Wang, S. -. L. PY - 2011 DA - 2011// TI - A nation-wide multicenter 10-year (1999-2008) retrospective clinical epidemiological study of female breast cancer in China JO - BMC Cancer VL - 11 UR - https://doi.org/10.1186/1471-2407-11-364 DO - 10.1186/1471-2407-11-364 ID - Li2011 ER - TY - JOUR AU - Zhang, B. -. L. AU - Sivasubramaniam, P. G. AU - Zhang, Q. AU - Wang, J. AU - Zhang, B. AU - Gao, J. -. D. PY - 2015 DA - 2015// TI - Trends in radical surgical treatment methods for breast malignancies in China: a multicenter 10-year retrospective study JO - Oncologist VL - 20 UR - https://doi.org/10.1634/theoncologist.2014-0281 DO - 10.1634/theoncologist.2014-0281 ID - Zhang2015 ER - TY - JOUR AU - Shan, Z. AU - Jing-Qiao, B. AU - Jing, L. AU - Jin-Hu, F. AU - Yi, P. AU - Qing-Kun, S. PY - 2012 DA - 2012// TI - The pathologic characteristics of breast cancer in China and its shift during 1999-2008: a national-wide multicenter cross-sectional image over 10 years JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.27513 DO - 10.1002/ijc.27513 ID - Shan2012 ER - TY - JOUR AU - Youden, W. J. PY - 1950 DA - 1950// TI - Index for rating diagnostic tests JO - Cancer VL - 3 UR - https://doi.org/3.0.CO;2-3 DO - 3.0.CO;2-3 ID - Youden1950 ER - TY - JOUR AU - Buzdar, A. U. AU - Ibrahim, N. K. AU - Francis, D. AU - Booser, D. J. AU - Thomas, E. S. AU - Theriault, R. L. PY - 2005 DA - 2005// TI - Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.07.032 DO - 10.1200/JCO.2005.07.032 ID - Buzdar2005 ER - TY - JOUR AU - Fishman, J. E. AU - Milikowski, C. AU - Ramsinghani, R. AU - Velasquez, M. V. AU - Aviram, G. PY - 2003 DA - 2003// TI - US-guided core-needle biopsy of the breast: how many specimens are necessary? JO - Radiology. VL - 226 UR - https://doi.org/10.1148/radiol.2263011622 DO - 10.1148/radiol.2263011622 ID - Fishman2003 ER - TY - JOUR AU - Melotti, M. K. AU - Berg, W. A. PY - 2000 DA - 2000// TI - Core needle breast biopsy in patients undergoing anticoagulation therapy: preliminary results JO - AJR Am J Roentgenol VL - 174 UR - https://doi.org/10.2214/ajr.174.1.1740245 DO - 10.2214/ajr.174.1.1740245 ID - Melotti2000 ER - TY - JOUR AU - Traina, A. AU - Agostara, B. AU - Marasà, L. AU - Calabrò, M. AU - Zarcone, M. AU - Carruba, G. PY - 2006 DA - 2006// TI - HER2/neu expression in relation to Clinicopathologic features of breast Cancer patients JO - Ann N Y Acad Sci VL - 1089 UR - https://doi.org/10.1196/annals.1386.029 DO - 10.1196/annals.1386.029 ID - Traina2006 ER - TY - JOUR AU - Bouchbika, Z. AU - Benchakroun, N. AU - Taleb, A. AU - Jouhadi, H. AU - Tawfiq, N. AU - Sahraoui, S. PY - 2012 DA - 2012// TI - Association between overexpression of Her-2 and other Clinicopathologic prognostic factors in breast Cancer in Morocco JO - J Cancer Therapy VL - 03 UR - https://doi.org/10.4236/jct.2012.325099 DO - 10.4236/jct.2012.325099 ID - Bouchbika2012 ER - TY - JOUR AU - Guo, Q. AU - Kai, C. AU - Lin, X. AU - Yi, S. AU - Rui, X. AU - Yan, D. PY - 2017 DA - 2017// TI - A nomogram to predict HER2 status in breast cancer patients with HER2-borderline disease as determined via immunohistochemistry JO - Oncotarget. VL - 8 ID - Guo2017 ER - TY - JOUR AU - Iasonos, A. AU - Schrag, D. AU - Raj, G. V. AU - Panageas, K. S. PY - 2008 DA - 2008// TI - How to build and interpret a nomogram for cancer prognosis JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.12.9791 DO - 10.1200/JCO.2007.12.9791 ID - Iasonos2008 ER - TY - JOUR AU - Balachandran, V. P. AU - Gonen, M. AU - Smith, J. J. AU - Dematteo, R. P. PY - 2015 DA - 2015// TI - Nomograms in oncology: more than meets the eye JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71116-7 DO - 10.1016/S1470-2045(14)71116-7 ID - Balachandran2015 ER -